Customer Publication
The histone methyltransferase ASH1L protects against bone loss by inhibiting osteoclastogenesis
Journal: Cell Death & Differentiation (2024)
Institution: Department of Biochemistry, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Research Areas: Bone Diseases
Cell Lines: BMM (bone marrow-derived macrophages)
Summary: Absent, small, or homeotic1-like (ASH1L) is a histone lysine methyltransferase that generally functions as a transcriptional activator in controlling cell fate. By conditional deletion of Ash1l in osteoclast progenitors of mice ASH1L, this study showed that deficiency resulted in osteoporosis and potentiation of osteoclastogenesis in vivo and in vitro, proving that ASH1L is a critical checkpoint during osteoclastogenesis. HoloMonitor provided data showing that a deletion of ASH1L resulted in decreased cell proliferation.